The short version of peptide mapping fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-12-26 and is reviewed periodically as new material appears.
Regulatory and quality discussions place the peptide within established guidance for synthetic peptides and biologics. Forced degradation studies, in which samples are exposed to heat, acid, base, peroxide, and light, identify likely degradation products and validate the selectivity of analytical methods. Reference standards allow comparison across laboratories and production batches. Purity specifications reported in the literature usually combine chromatographic purity with mass confirmation. Which impurity thresholds are meaningful for long-term behavior is still debated, and no single universal specification has been adopted across all jurisdictions.
Routine characterization of the peptide relies on reversed-phase high-performance liquid chromatography for purity assessment, usually with ultraviolet detection near 214 nanometers. Intact mass measurement by liquid chromatography coupled to mass spectrometry confirms molecular identity against a theoretical value. Sequence-level confirmation uses enzymatic digestion followed by tandem mass spectrometry, an approach known as peptide mapping. Amino acid analysis gives an independent check on composition. Circular dichroism spectra are used to estimate helical content in aqueous buffer.
Stability depends strongly on physical form. The dry powder is generally regarded as stable for extended periods when held at or below minus twenty degrees Celsius in a sealed, desiccated container. In solution, degradation pathways include deamidation of asparagine and glutamine residues, oxidation of methionine, and aggregation. Reaction rates for these pathways rise with temperature. Repeated freezing and thawing of solutions promotes aggregation, and light exposure can accelerate some oxidative changes. Buffer composition and pH influence which pathway dominates at a given temperature.
At the receptor level, tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. Both belong to the class B family of G protein-coupled receptors and signal largely through cyclic AMP accumulation. The compound binds the two receptors with differing affinity, and the pattern of signaling at each site is described in the literature as biased rather than simply proportional to occupancy. Tissues carrying these receptors include pancreatic islets, adipose tissue, the central nervous system, and the gastrointestinal tract. The relative weight of each receptor population in producing metabolic effects continues to be studied.
Published work supports the view that engaging two incretin receptors produces changes in glucose handling and body weight larger than those seen with single-receptor activation. Why that difference arises is not fully settled. Open questions include how much of the observed weight effect depends on central versus peripheral signaling, and whether the two receptors form interacting complexes. Most reported findings come from controlled trials and animal models, and translation between species is imperfect. Further research is expected to refine these points over time.
Tirzepatide is a synthetic peptide built from 39 amino acid residues. Its sequence is related to human glucose-dependent insulinotropic polypeptide, with modifications that include a C-terminal extension and a C20 fatty diacid joined through a linker. Those changes raise the molecule's affinity for serum albumin, which slows renal filtration and lengthens the time it stays in circulation. The free base has an average molecular mass near 4813.5 daltons. The compound is made by solid-phase peptide synthesis followed by chromatographic purification.
| Property | Value | Notes |
|---|---|---|
| Primary purity method | Reversed-phase HPLC | Ultraviolet detection near 214 nm |
| Identity confirmation | Intact mass by LC-MS | Compared with theoretical average mass |
| Sequence verification | Enzymatic peptide mapping | Tandem mass spectrometry of fragments |
| Common degradation route | Deamidation and oxidation | Rate increases with pH and temperature |
| Reference material | Lyophilized peptide standard | Stored desiccated below -20 °C |
Routine characterization relies on reversed-phase high-performance liquid chromatography, often coupled to mass spectrometry, to confirm identity and estimate purity. Peptide mapping after enzymatic digestion verifies the amino acid sequence and locates appended groups such as the fatty acid chain. Size-exclusion chromatography detects aggregates and fragments, while ion-exchange chromatography resolves charge variants. Circular dichroism and nuclear magnetic resonance supply secondary and higher-order structural information in research settings. No single technique covers every attribute, so laboratories combine orthogonal methods and compare outcomes against a reference standard where one exists.
Purified material is typically handled as a lyophilized powder kept at or below minus twenty degrees Celsius, shielded from light and moisture. In that state the solid remains stable for extended periods, although repeated freeze-thaw cycling can encourage aggregation. Once dissolved, aqueous solutions are less durable and are generally held cold and used within a brief window. Buffer composition, pH and ionic strength all influence degradation rates, and mildly acidic to neutral conditions are commonly examined. Actual shelf life depends on formulation, concentration and container, so stability limits are established experimentally rather than assumed.
Tirzepatide is a synthetic peptide built from 39 amino acid residues. Its backbone derives from the native glucose-dependent insulinotropic polypeptide sequence, altered at several positions to resist enzymatic cleavage. A fatty diacid group attached through a linker extends plasma residence time by promoting reversible binding to serum albumin. The molecule carries a net negative charge near physiological pH and has a reported molecular weight close to 4813 daltons. These features separate it from shorter incretin analogs and account for its prolonged dosing interval.
Pharmacologically, tirzepatide activates two distinct G protein-coupled receptors: the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. Binding at each target triggers cyclic AMP accumulation and downstream signaling in pancreatic beta cells, adipose tissue and the central nervous system. Because the two pathways overlap only partially, the combined effect on insulin secretion, glucagon suppression and appetite signaling differs from that of selective single-receptor compounds. Affinity is not equal across the two targets, and the clinical meaning of that imbalance remains an area of active study.
Clinical research programs have evaluated tirzepatide in adults with type 2 diabetes and in adults with obesity or excess weight. Trials generally reported reductions in glycated hemoglobin and body weight across treatment periods of several months. Since these studies enrolled defined populations under controlled conditions, the findings describe group averages rather than individual outcomes. Open questions include the durability of effects after treatment stops, variation among subgroups, and the long-term consequences of sustained dual receptor stimulation. Published trial summaries should be consulted for exact measurements rather than secondary accounts.
Peptide-based pharmaceutical products such as tirzepatide require controlled temperature management to preserve structural integrity. Manufacturer labeling generally specifies refrigeration at 2 to 8 degrees Celsius before first use, with protection from light and freezing. Exposure to repeated temperature cycling can promote aggregation or deamidation, which alters the analytical profile even when the visible solution appears unchanged. Once a product is in use, the permitted storage window and temperature range are defined by the specific labeled presentation rather than by general peptide rules.
Identity and purity assessment of tirzepatide relies primarily on reversed-phase high-performance liquid chromatography coupled with ultraviolet detection. Mass spectrometry, often in electrospray ionization mode, confirms the molecular mass and detects sequence-related impurities. Peptide mapping after enzymatic digestion provides residue-level confirmation of the backbone. Each method addresses a different question: chromatography for purity and related substances, mass measurement for identity, and mapping for sequence fidelity. No single technique covers all three.
Development of tirzepatide took place under a research program that sought to test whether simultaneous engagement of two incretin receptors would produce greater metabolic effects than single-receptor agonism. Clinical trials were organized into the SURPASS series for type 2 diabetes and the SURMOUNT series for obesity and weight management. Regulatory clearance for type 2 diabetes came in 2022 in the United States, followed by approval for chronic weight management in 2023. The trial programs reported reductions in glycated hemoglobin and body weight relative to comparators, though long-term cardiovascular and durability data continue to accumulate.
The peptide backbone contains 39 amino acids and includes alpha-aminoisobutyric acid residues, which are not among the standard proteinogenic set. A C20 fatty diacid moiety is attached through a linker, allowing the compound to bind serum albumin and extend its circulation time. This albumin binding is the main reason the molecule supports once-weekly administration rather than more frequent dosing. The measured molecular mass is approximately 4,813 daltons, placing it firmly in the peptide rather than small-molecule class.
=== Liposomes === A mechanism for liposome transport across the BBB is lipid-mediated free diffusion, a type of facilitated diffusion, or lipid-mediated endocytosis. There exist many lipoprotein receptors which bind lipoproteins to form complexes that in turn transport the liposome nano-delivery system across the BBB. Apolipoprotein E (apoE) is a protein that facilitates transport of lipids and cholesterol. ApoE constituents bind to nanoparticles, and then this complex binds to a low-density lipoprotein receptor (LDLR) in the BBB and allows transport to occur.
=== Linus Pauling Institute === Robinson was the president, director, and a research professor with tenure at the institute. In June 1978, Robinson was asked to consult with the Executive Committee of the Linus Pauling Institute regarding important decisions involving the Institute. The members of the Executive Committee included Robinson, Pauling, and Executive Vice President Richard Hicks. The same day Robinson was asked to consult, he (Robinson) dismissed Hicks by terminating the fund raising services agreement employing Hicks, claiming that Hicks had failed to generate the substantial donations expected of him. Disturbed by Robinson's swift actions against Hicks, Pauling declared that he no longer had "trust and confidence in Robinson", and asked him to resign immediately. Robinson requested thirty days to consider the resignation and ultimately refused. Pauling called a meeting of the board of trustees regarding Robinson's refusal to resign. The board granted Robinson a leave of absence, and passed all executive authority to Pauling, later electing him president and director of the institute.
=== Immune response === Cortisol prevents the release of substances in the body that cause inflammation. Cortisol is used to treat conditions resulting from overactivity of the B-cell-mediated antibody response. Examples include inflammatory and rheumatoid diseases, as well as allergies. Low-dose topical hydrocortisone, available as a nonprescription medicine in some countries, is used to treat skin problems such as rashes and eczema. Cortisol inhibits production of interleukin 12 (IL-12), interferon gamma (IFN-gamma), IFN-alpha, and tumor necrosis factor alpha (TNF-alpha) by antigen-presenting cells (APCs) and T helper cells (Th1 cells), but upregulates interleukin 4, interleukin 10, and interleukin 13 by Th2 cells. This change results in a shift toward a Th2 immune response rather than general immunosuppression. The activation of the stress system (and resulting increase in cortisol and Th2 shift) seen during an infection is believed to be a protective mechanism which prevents an over-activation of the inflammatory response. Cortisol can weaken the activity of the immune system. Cortisol prevents proliferation of T-cells by rendering the interleukin-2 producer T-cells unresponsive to interleukin-1, and unable to produce the T-cell growth factor IL-2. Cortisol downregulates the expression of the IL2 receptor IL-2R on the surface of the helper T-cell which is necessary to induce a Th1 'cellular' immune response.
Health Canada followed with similar label updates in 2021, and Australia's Therapeutic Goods Administration aligned all SSRI and SNRI product information in 2024, noting that venlafaxine already carried a warning about persistent sexual dysfunction.
Sources: en.wikipedia.org
=== Lobbying by competitors === According to The Washington Post, Meta hired the Republican consulting firm Targeted Victory to run a campaign aimed at turning public opinion against TikTok. Internal emails revealed that the firm sought to portray TikTok as "the real threat" and encouraged headlines such as "From dances to danger: how TikTok has become the most harmful social media space for kids." Operatives promoted stories to local media that tied TikTok to allegedly dangerous trends among teenagers, including the 2021 "devious lick" vandalism challenge, which evidence shows originated on Facebook. The campaign also sought to deflect attention from criticisms of Meta's own privacy and antitrust issues. A Meta spokesperson defended the effort, saying that all platforms, including TikTok, should face equal scrutiny. An analysis estimated that Meta, the parent company of Facebook and Instagram, could gain between $2.46 billion and $3.38 billion in advertising revenue if TikTok were banned. Reddit CEO Steve Huffman has publicly advocated for a ban on TikTok, calling the app "fundamentally parasitic" and a "spyware" in 2020.
=== Category:EC 6.2 (form carbon–sulfur bonds) === EC 6.2.1.1: Acetate—CoA ligase EC 6.2.1.2: Medium-chain acyl—CoA ligase EC 6.2.1.3: Long-chain-fatty-acid—CoA ligase EC 6.2.1.4: Succinate—CoA ligase (GDP-forming) EC 6.2.1.5: Succinate—CoA ligase (ADP-forming) EC 6.2.1.6: Glutarate—CoA ligase EC 6.2.1.7: Cholate—CoA ligase EC 6.2.1.8: Oxalate—CoA ligase EC 6.2.1.9: Malate—CoA ligase EC 6.2.1.10: Acid—CoA ligase (GDP-forming) EC 6.2.1.11: Biotin—CoA ligase EC 6.2.1.12: 4-Coumarate—CoA ligase EC 6.2.1.13: Acetate—CoA ligase (ADP-forming) EC 6.2.1.14: 6-carboxyhexanoate—CoA ligase EC 6.2.1.15: Arachidonate—CoA ligase EC 6.2.1.16: Acetoacetate—CoA ligase EC 6.2.1.17: Propionate—CoA ligase EC 6.2.1.18: Citrate—CoA ligase EC 6.2.1.19: Long-chain-fatty-acid-luciferin-component ligase EC 6.2.1.20: Long-chain-fatty-acid-(acyl-carrier-protein) ligase EC 6.2.1.21: Transferred entry: 6.2.1.30 EC 6.2.1.22: (citrate (pro-3S)-lyase) ligase EC 6.2.1.23: Dicarboxylate—CoA ligase EC 6.2.1.24: Phytanate—CoA ligase EC 6.2.1.25: Benzoate—CoA ligase EC 6.2.1.26: o-Succinylbenzoate—CoA ligase EC 6.2.1.27: 4-hydroxybenzoate—CoA ligase EC 6.2.1.28: 3-alpha,7-alpha-dihydroxy-5-beta-cholestanate—CoA ligase EC 6.2.1.29: Transferred entry: 6.2.1.7 EC 6.2.1.30: Phenylacetate—CoA ligase EC 6.2.1.31: 2-furoate—CoA ligase EC 6.2.1.32: Anthranilate—CoA ligase EC 6.2.1.33: 4-chlorobenzoate—CoA ligase EC 6.2.1.34: trans-Feruloyl—CoA synthase EC 6.2.1.35: ACP-SH:acetate ligase EC 6.2.1.36: 3-hydroxypropionyl-CoA synthase EC 6.2.1.37: 3-hydroxybenzoate—CoA ligase EC 6.2.1.38: (2,2,3-trimethyl-5-oxocyclopent-3-enyl)acetyl-CoA synthase EC 6.2.1.39: (butirosin acyl-carrier protein)—L-glutamate ligase EC 6.2.1.40: 4-Hydroxybutyrate—CoA ligase EC 6.2.1.41: 3-((3aS,4S,7aS)-7a-methyl-1,5-dioxo-octahydro-1H-inden-4-yl)propanoate—CoA ligase EC 6.2.1.42: 3-oxocholest-4-en-26-oate—CoA ligase EC 6.2.1.43: 2-hydroxy-7-methoxy-5-methyl-1-naphthoate—CoA ligase EC 6.2.1.44: 3-(methylthio)propionyl—CoA ligase EC 6.2.1.45: E1 ubiquitin-activating enzyme EC 6.2.1.46: L-allo-Isoleucine—holo-CmaA peptidyl-carrier protein ligase EC 6.2.1.47: Medium-chain-fatty-acid-(acyl-carrier-protein) ligase EC 6.2.1.48: Carnitine—CoA ligase EC 6.2.1.49: Long-chain fatty acid adenylyltransferase FadD28 EC 6.2.1.50: 4-hydroxybenzoate adenylyltransferase FadD22 EC 6.2.1.51: 4-hydroxyphenylalkanoate adenylyltransferase FadD29 EC 6.2.1.52: L-Firefly luciferin—CoA ligase EC 6.2.1.53: L-Proline—L-prolyl-carrier protein ligase EC 6.2.1.54: D-Alanine—D-alanyl-carrier protein ligase EC 6.2.1.55: E1 SAMP-activating enzyme
Linus Pauling Online a Pauling portal created by Oregon State University Libraries Crick, Francis, "The Impact of Linus Pauling on Molecular Biology" (transcribed from video at the 1995 Oregon State University symposium) The Ava Helen and Linus Pauling Papers at the Oregon State University Libraries The Pauling Catalogue Center for Oral History. "Linus C. Pauling". Science History Institute. Sturchio, Jeffrey L. (1987-04-06). Linus C. Pauling, Transcript of an Interview Conducted by Jeffrey L. Sturchio in Denver, Colorado on 6 April 1987 (PDF). Philadelphia, PA: Chemical Heritage Foundation. The Pauling Blog Linus Pauling (1901–1994) Berkeley Conversations With History interview Linus Pauling Centenary Exhibit Linus Pauling from The Dictionary of Unitarian and Universalist Biography Archived October 16, 2018, at the Wayback Machine "It's in the Blood! A Documentary History of Linus Pauling, Hemoglobin and Sickle Cell Anemia – Special Collections & Archives Research Center – Oregon State University". Oregon State University Library. Retrieved 2015-02-25. The Linus Pauling Institute at Oregon State University Publications of Pauling The Linus Pauling Papers – Profiles in Science, National Library of Medicine Linus Pauling Archived July 19, 2019, at the Wayback Machine Documentary produced by Oregon Public Broadcasting Oral history interview with Linus C. Pauling from Science History Institute Digital Collections
Sources: en.wikipedia.org
Kastl has made appearances in the blockbuster films Hulk and War of the Worlds. Kastl had a recurring role on Scrubs for 8 years from 2001 to 2009 as Dr. Doug Murphy, the totally incompetent doctor who finally finds his calling as a very competent forensic pathologist. However, he asked to be allowed to "sit out" the fourth season of Scrubs as he had broken both his heels in a ski jumping accident. This was written into the show to keep the character around and, as described on the DVD commentary by creator Bill Lawrence, "We felt that breaking both of his feet was a very 'Doug' thing to do, so we decided to write it into the show." He had a recurring role, as FBI agent Todd Jaracki, for the single season of Patrick Swayze's The Beast (2009).
It entails a loss of fuel-efficiency as well as power by converting the output of the diesel engine into electricity. While both generators and electric motors are known to be very efficient, their efficiency nevertheless falls short of 100 percent. It requires an additional component in the form of a dedicated generator. Since the electric motor is always used to drive the propeller it can no longer step in to take on generator service as well. It does not allow the diesel engine and the electrical motor to join forces by simultaneously driving the propeller mechanically for maximum speed when the submarine is surfaced or snorkeling. This may, however, be of little practical importance inasmuch as the option it prevents is one that would leave the submarine at a risk of having to dive with its batteries at least partly depleted. The reason why diesel–electric transmission has become the dominant alternative in spite of these disadvantages is of course that it also comes with many advantages and that, on balance, these have eventually been found to be more important. The advantages include the following:
=== Other inorganic compounds === Oxyhalides and oxysulfides of protactinium are known. PaOBr3 has a monoclinic structure composed of double-chain units where protactinium has coordination 7 and is arranged into pentagonal bipyramids. The chains are interconnected through oxygen and bromine atoms, and each oxygen atom is related to three protactinium atoms. PaOS is a light-yellow, non-volatile solid with a cubic crystal lattice isostructural to that of other actinide oxysulfides. It is obtained by reacting protactinium(V) chloride with a mixture of hydrogen sulfide and carbon disulfide at 900 °C. In hydrides and nitrides, protactinium has a low oxidation state of about +3. The hydride is obtained by direct action of hydrogen on the metal at 250 °C, and the nitride is a product of ammonia and protactinium tetrachloride or pentachloride. This bright yellow solid is thermally stable to 800 °C in vacuum. Protactinium carbide (PaC) is formed by the reduction of protactinium tetrafluoride with barium in a carbon crucible at a temperature of about 1400 °C. Protactinium forms borohydrides, which include Pa(BH4)4. It has an unusual polymeric structure with helical chains, where the protactinium atom has coordination number of 14 and is surrounded by six BH4− ions.
Sources: en.wikipedia.org
Peptide mapping with tandem mass spectrometry is the standard approach. The peptide is digested with an enzyme such as trypsin, and the resulting fragments are matched against the expected sequence.
Higher pH and elevated temperature both increase deamidation rates. Holding solutions at low temperature and near-neutral to slightly acidic pH reduces the extent of the reaction.
Removing water slows hydrolysis and aggregation. The dry powder tolerates longer storage intervals than a solution kept at the same temperature.
It is a synthetic peptide and a dual agonist of two incretin receptors. It is not a small molecule, and it is not structurally related to the older single-receptor peptide agonists.